NetworkNewsWire
Editorial Coverage: Cannabis derivatives have
been used medicinally around the world for millennia. However,
concerns surrounding potential dangers and abuse of marijuana’s
psychoactive component THC (tetrahydrocannabinol) led to the
banning of medicinal cannabis early in the 20th Century. Recent
scientific studies, however, have given new credence to the wisdom
from millennia ago and have scientifically proven the medical
efficacy of certain cannabinoids for developing new approaches to
treating diseases with high unmet medical needs. Global scientists,
researchers, and biopharmaceutical companies are now focused on
cannabinoids that have therapeutic potential. One pioneering
biopharmaceutical company, InMed Pharmaceuticals, Inc.
(CSE: IN) (OTCQB: IMLFF) (IMLFF
profile), has triggered a paradigm shift in
discovering potential breakthrough cannabinoid-based therapies.
InMed Pharmaceuticals utilizes its robust, proprietary biosynthesis
process to isolate and create pharmaceutical grade, bio-identical
cannabinoids in the laboratory where it can cost-effectively
manufacture any of the 90+ cannabinoid compounds at
pharmaceutical-grade (greater than 95 percent) purity. InMed also
employs its proprietary bioinformatics assessment tool to determine
therapeutic approaches for specific diseases by analyzing
pharmaceutical and cannabinoid structures to identify associations
between approved pharmaceuticals and particular cannabinoids to
attain parallel biological responses. The company’s combination of
comprehensive proprietary processes sets it apart from others
trying to compete in this arena. Other companies on the trail of
new cannabinoid medicines and drug classes include GW
Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals (NASDAQ:
ZYNE), Cara Therapeutics, Inc. (NASDAQ: CARA) and
Axim Biotechnologies (OTC: AXIM).
Other biopharmaceutical companies may produce cannabinoids in
the laboratory using chemical synthesis, but there’s a litany of
drug development efforts with synthetic molecules that have failed.
The proprietary biosynthesis process used by InMed
Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) is
unique. Producing cannabinoids that are identical to naturally
occurring compounds is transformative for drug development. By
using its proprietary process, InMed is able to manufacture exact
cannabinoid replicas for use in research. This novel breakthrough
gives InMed scientists the ability to manufacture all 90+
cannabinoid compounds identical to those found in nature and the
ability to consistently, reliably and accurately test efficacy and
safety. In addition, InMed’s cost-effective biosynthesis process
enhances production, purification, and quality control as opposed
to other chemical manufacturing methods. InMed's biopharmaceutical
approach to the production of pharmaceutical grade, bio-identical
cannabinoids is disruptive in the development of pharmaceutical
cannabinoids for research and drug creation. The company’s
high-yield manufacturing process also provides simpler scale-up and
systems optimization, as well as the production of minor
cannabinoids that are economically impractical to extract from
plant sources.
To protect this invaluable asset, InMed has filed a provisional
patent for the biosynthesis of cannabinoids (http://nnw.fm/RPTj0), and the company continues to use
the technology to expand its pipeline for treating a variety of
medical conditions.
InMed’s cannabinoid biosynthesis process is complemented by its
bioinformatics drug and disease targeting tool. Bioinformatics is a
high-efficiency, computer-assisted approach to predicting the
therapeutic potential and medicinal properties of individual
cannabinoids against particular medical conditions. InMed’s
proprietary approach applies comprehensive algorithms to integrate
the data from various bioinformatics databases, including a vast
database of the chemical structures of approved pharmaceuticals,
with InMed’s proprietary cannabinoid database and know-how.
Study results published earlier this year by InMed in the
European Journal of Pain (NR July 27, 2017) highlighted
the topical application of cannabinoids to successfully treat
peripheral pain, and on October 17, 2017 the company issued an
update on its cannabinoid-based pain drug program (http://nnw.fm/o8rPL) to include the potential of
non-THC cannabinoids for pain management.
Pre-clinical results in the development of the company’s INM-405
candidate for the treatment of pain suggest that peripheral
application of certain cannabinoid compounds, alone or in
combination, is effective in the treatment of craniofacial muscle
pain disorders such as temporomandibular disorders (TMD) and
trigeminal neuralgia (TN) — without any observed central nervous
system side effects.
TN in particular is known for symptoms involving intense and
uncontrollable face and jaw spasms, causing pain that is so severe
it has been nicknamed “the suicide disease.” It is estimated that
12 new cases of TN occur per 100,000 persons every year, according
to the National Institute of Neurological Disorders and
Stroke. Sufferers have found some relief smoking marijuana,
but must do so frequently and are subject to protracted
psycho-activity caused by THC. InMed recognizes the need and market
opportunity for non-opioid alternatives to treat chronic and severe
pain with limited side effects.
InMed has since filed a provisional patent application for
INM-405 and other unique compositions as cannabinoid-based topical
therapies for the treatment of pain (http://nnw.fm/K0MRo), noting the need for therapies
centered on specific non-psychoactive cannabinoids.
"There remains a significant need in the field of analgesia for
a product that can treat pain via a topical route of
administration, which would reduce systemic exposure and any
associated side effects," Dr. Sazzad Hossain, chief scientific
officer of InMed Pharmaceuticals and a co-inventor on the patent,
stated in the October 3 press release. “InMed's focus on
non-psychoactive cannabinoids further reduces concerns regarding
addiction, a key concern in pain management.”
Pain management represents only a sliver of the market potential
for InMed’s pipeline as it relates to broader demand for
cannabinoid-based therapies. The company’s comprehensive
pharmaceutical approach to cannabinoid drug development may likely
set a new standard in cannabinoid pharmacology.
As evidenced by the size and application of such innovations by
other biotech leaders, the market opportunity for InMed could be
substantial.
One of the most recognized names in cannabinoid medicine is
GW Pharmaceuticals plc (NASDAQ: GWPH). Researching
cannabinoids since 1998, the company is focused on developing and
commercializing therapeutics from its cannabinoid product platform
across a range of disease areas. GW’s lead cannabinoid product
candidate is a liquid formulation of pure plant-derived cannabidiol
(CBD). The company has established industry leadership through the
early development of plant-derived therapeutics, drug discovery
processes, manufacturing and regulatory expertise, and a portfolio
of intellectual properties. The company developed the world’s first
prescription cannabis-derived medicine, Sativex, which is approved
for use in countries outside of the United States for the treatment
of multiple sclerosis spasticity. GW’s lead cannabidiol product
candidate, Epidiolex, is in development for the treatment of a
number of rare childhood-onset epilepsy disorders.
Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a
clinical-stage specialty pharmaceutical company dedicated to
developing and commercializing innovative pharmaceutically produced
transdermal cannabinoid treatments for patients with high unmet
medical needs. Engaged in the research and development of
cannabinoid drugs, the company has developed a synthetic
transdermal cannabinoid product in the form of a gel that enables
compounds to pass through the skin and into the blood supply. A
skin patch is also available. Zynerba’s development pipeline
includes patent-protected pharmaceutically-produced transdermal
cannabinoid products. The company has been working on
cannabinoid-based treatments for Fragile X syndrome, epilepsy,
osteoarthritis, fibromyalgia and peripheral neuropathic pain.
Cara Therapeutics, Inc. (NASDAQ: CARA) is a
clinical-stage biotech company looking to change how pain is
treated. Its portfolio includes opioid-based products,
anesthetic-based drugs, and analgesics that seek to alleviate itch
and pain. Cara is developing a new class of medicine called Kappa
Opioid Receptor Agonists (KORAs). KORAs target a completely
different receptor in the body, the kappa opioid receptor, to treat
pain in a fundamentally new way. The company’s lead pipeline
product, CR845, is a peripherally acting type of KORAs. To date,
CR845 has shown in phase II clinical trials promising pain relief
without many of the traditional side effects of opioids and
NSAIDs.
Axim Biotechnologies (OTCQB: AXIM) engages in
the research, development, and production of pharmaceutical,
nutraceutical, and cosmetic products. It focuses on the treatment
of pain, spasticity, anxiety, and other medical disorders with the
application of cannabinoid based products. Research in the use of
molecularly modified cannabinoids as neuroprotectants is currently
being conducted and the use of industrial hemp-derived
CBG-containing (cannabigerol) formulations for dermatological
applications is also being researched. The company’s MedChewRx™ is
undergoing clinical studies. The company’s chewing gum is the first
preparation of its kind, under study for not only its proprietary
active pharmaceutical ingredients but also for unique additional
benefits via the act of mastication.
The medicinal wisdom from millennia ago is being borne out by
the science of today. There’s immense promise for patients in
medicinal cannabis therapies and incredible economic opportunity
for companies like InMed using innovative technology with the goal
of bringing blockbuster cannabis-based drugs to market.
For more information on InMed Pharmaceuticals, please visit:
InMed
Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com